- 专利标题： USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJOGREN'S SYNDROME
-
申请号： US16075066申请日： 2017-02-10
-
公开(公告)号： US20190038628A1公开(公告)日： 2019-02-07
- 发明人: Bruno BIETH , Christoph BURKHART , Andreas CHRIST , Stefan DE BUCK , Christoph KALIS , Sam LINDGREN
- 申请人： Novartis AG
- 优先权： EP16155123.9 20160210; EP16186188.5 20160829
- 国际申请： PCT/IB2017/050743 WO 20170210
- 主分类号： A61K31/519
- IPC分类号： A61K31/519 ; A61P37/00
摘要：
The invention relates to the use of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one or pharmaceutically acceptable salts thereof for the treatment of primary Sjögren's Syndrome.
信息查询
IPC分类:
